GlaxoSmithKline (GSK) has filed a lawsuit against Moderna in Delaware federal court, accusing the biotech firm of infringing on its patents related to messenger RNA (mRNA) technology used in the COVID-19 vaccine Spikevax. GSK claims that Moderna's lipid nanoparticles for mRNA delivery violate several of its patents, which were developed over a decade ago by a team led by vaccinologist Christian Mandl. The litigation seeks unspecified monetary damages, and GSK is open to licensing the patents under reasonable terms. This lawsuit adds to the ongoing patent disputes in the pharmaceutical industry, including a previous case GSK brought against Pfizer and BioNTech. Moderna has expressed its intention to defend itself vigorously against the claims. Both companies face declining vaccine sales, with Moderna reporting $6.7 billion in revenue from Spikevax last year.